T halidomide, originally marketed as a nonaddictive nonbarbiturate sedative, was responsible in the 1950s and 1960s for birth defects in more than 10,000 children (1, 2) . Thalidomide exhibits potent antiangiogenic and immunomodulatory effects, and is currently used around the world to treat a range of conditions, most notably multiple myeloma and erythema nodosum leprosum (ENL; an inflammatory complication of leprosy) (2, 3) . However, long-term use of Thalidomide in adult patients can result in detrimental side effects, such as peripheral neuropathy (4, 5) , and carries the risk of inducing birth defects. Indeed, despite careful controls on Thalidomide use and distribution, a large number of babies with Thalidomide embryopathy have been born in the last two decades in Brazil where it is administered mainly for the treatment of leprosy and its complications (6, 7) . Consequently, there is intense interest in developing a more potent anti-inflammatory form of Thalidomide with enhanced clinical benefit, but fewer side effects.
Lenalidomide, a structural analog of Thalidomide licensed for use around the world, is clinically more potently anti-inflammatory than Thalidomide, with potentially fewer side effects (8, 9) . However, long-term treatment with Lenalidomide can result in peripheral neuropathy (10, 11) and, as yet, its teratogenic properties are uncertain, with only limited studies performed to date (12) . Another Thalidomide analog, Pomalidomide, has shown promising treatment of relapsed and refractory multiple myeloma in phase I and phase II clinical trials, including in patients that have been treated previously with Thalidomide and Lenalidomide (13) (14) (15) . However, whether Pomalidomide is neurotoxic and/or teratogenic is understudied and is the focus of this study.
Using a combination of in vivo and in vitro assays for teratogenesis, inflammation, angiogenesis, and neurotoxicity, we have compared the relative activities of Thalidomide, Lenalidomide, and Pomalidomide. We found that Pomalidomide was potently anti-inflammatory in embryonic and in vitro assays at significantly lower concentrations than either Thalidomide or Lenalidomide. Moreover, at potently anti-inflammatory concentrations Lenalidomide was also teratogenic, antiangiogenic, and neurotoxic, whereas Pomalidomide was not. We further found that Pomalidomide, but not Lenalidomide, was cell specific, inhibiting inflammatory response cells but not endothelial cells. We conclude that our unique series of in vitro and in vivo assays provides a fast and effective mechanism for determining drug efficacy and potential side effects, and that Pomalidomide likely represents a more effective and potentially safer option for treatment of multiple myeloma, ENL, and other conditions.
Results

Pomalidomide Has Potent Anti-Inflammatory Activity at Significantly Lower Concentrations than Thalidomide or Lenalidomide in in Vivo
Assays. Previous studies using in vitro assays have indicated Pomalidomide is more potently anti-inflammatory than Thalidomide and Lenalidomide (16) (17) (18) (19) . Pomalidomide's actions in vivo and its potential to cause adverse side effects are unclear.
Here the immunomodulatory potency of Thalidomide and analogs was investigated using both in vivo and in vitro approaches. First we made use of Tg (MPO::EGFP) 114 transgenic zebrafish, which express GFP-tagged myeloperoxidase, a marker of neutrophils (20) . To induce an inflammatory response, a small cut was made in the tail fin at 72 h postfertilization (hpf), and the number of fluorescent neutrophils at the wound site quantified 24 h later (right side of line in Fig. 1 A-F ). Compounds were added at the time of injury. In the presence of vehicle alone (0.1% DMSO), cutting the tail induced a significant increase in the number of neutrophils throughout the embryo, with (mean ± SEM) 10.33 ± 0.67 cells at the wound site ( Fig. 1 A-C; n = 21). Treatment with Thalidomide ( Fig. 1D ; n = 32), Lenalidomide ( Fig. 1E ; n = 42), or Pomalidomide (n = 105; Fig. 1F ) inhibited the injury-induced induction of neutrophils in a dose-dependent manner (Fig. 1G) . With Thalidomide exerting 50% activity (AC50) at 200 μg/mL (775 μM), Lenalidomide AC50 at 140 μg/ mL (542 μM), and Pomalidomide AC50 at 35 μg/mL (128 μM). We found Thalidomide and Lenalidomide were maximally effective (Emax) at 250 μg/mL (968 μM) and 200 μg/mL (772 μM), respectively, reducing the number of fluorescent cells at the wound site to 2.10 ± 0.75 (n = 7) and 4.6 ± 0.86 (n = 12), respectively. Pomalidomide, however, induced a comparable reduction in neutrophil number (3.66 ± 0.96; n = 28) at a three-to fourfold lower concentration (60 μg/mL; 219 μM; Fig. 1G ). These findings establish concentrations of Pomalidomide, Thalidomide, To whom correspondence should be addressed. E-mail: n.vargesson@abdn.ac.uk.
and Lenalidomide to induce anti-inflammatory responses in embryonic in vivo assays.
Thalidomide exerts its anti-inflammatory effects, at least in part through inhibition of TNF-α and COX2 production (16, 21) . To provide an additional, independent measure of the anti-inflammatory properties of each compound, we used lipopolysaccharides (LPS) to induce TNF-α and COX2 expression in a macrophage cell line, RAW 264.7, and quantified the effect of drug application using a TNF-α ELISA or qRT-PCR ( Fig. 1 I-K) . Thalidomide, Lenalidomide, and Pomalidomide all inhibited the induction of TNF-α and COX2 by LPS in a dose-dependent manner ( Fig. 1 H and J) , without any effect on cell viability (Fig. 1) . In this assay, the AC50 of TNF-α inhibition by Thalidomide was 125 μg/mL (484 μM), Lenalidomide was 40 μg/mL (155 μM), and Pomalidomide was 20 μg/mL (73 μM). The Emax of Pomalidomide (60 μg/mL; 219 μM) was substantially lower than Thalidomide (200-250 μg/mL; 968 μM) or Lenalidomide (200 μg/mL; 772 μM).
Lenalidomide, but Not Pomalidomide, Is Teratogenic. Thalidomide has well-characterized teratogenic effects, inducing severe developmental defects in limbs, eyes, and other organs in humans and animal models (1, 2, (22) (23) (24) (25) (26) (27) (28) . To investigate whether Lenalidomide and Pomalidomide are also teratogenic, we tested each compound in our established chicken and zebrafish models of Thalidomide-induced teratogenesis (26) . Each compound was tested at its maximal anti-inflammatory concentration, determined from our in vivo embryonic assays (Lenalidomide, 200 μg/mL; Pomalidomide, 60 μg/mL). Chicken embryos were treated at Hamburger and Hamilton (HH) St17-18 (day 2.5), a stage of rapid limb and head development, incubated for 6 d and the impact upon craniofacial and forelimb development analyzed ( Fig. 2 A-I ). In embryos treated with Lenalidomide, a normally patterned proximal-to-distal forelimb skeletal pattern developed ( Fig. 2 G, I ). However, compared with vehicle alone (0.1% DMSO; n = 14), the length of the humerus, hand plate and digits was decreased significantly ( Fig. 2G ; n = 14). The size of the eyes also was significantly smaller (Fig. 2 B-C′ and E; n = 6/14), with anophthalmia (no eyes) occurring in some cases. Beak defects were also observed ( Fig. 2B′ ; n = 5/14). In contrast, Pomalidomide has no significant effect on the development of these or any other structures in the embryos at the maximal anti-inflammatory concentration tested ( Similar results were obtained using zebrafish. Fish embryos at 24 hpf, a stage of rapid development and organogenesis, were incubated with compounds for 72 h, then fixed and analyzed. Neither Lenalidomide (200 μg/mL, n = 10) nor Pomalidomide (60 μg/mL, n = 10) had any effect on pectoral fin length ( Fig. 2 K′ and L′). However, compared with vehicle alone (0.1% DMSO, n = 10) Lenalidomide, but not Pomalidomide, induced microphthalmia (small eyes; n = 6/10; Fig. 2 K′ and L′). We conclude that at potent anti-inflammatory concentrations Lenalidomide, but not Pomalidomide, is teratogenic in chicken and zebrafish embryos.
Lenalidomide, but Not Pomalidomide, Is Antiangiogenic. Thalidomide exerts its teratogenic effects through inhibition of blood vessel development (26) . To test whether Lenalidomide and Pomalidomide also are antiangiogenic, we used a combination of in vivo and in vitro assays. First, we used the Fli1:EGFP transgenic zebrafish line, in which blood vessels are labeled with eGFP (29) , to study the effects of Lenalidomide and Pomalidomide on The qRT-PCR showed a significant decrease in COX2 expression following Thalidomide, Lenalidomide, and Pomalidomide treatment. Graphs represent mean ± SEM. Statistics: (H) statistical significance was analyzed using Student's t test. (I and J) Statistical significance was analyzed using one-way ANOVA with Tukey's post hoc test; *P < 0.05; **P < 0.005; ***P < 0.0005, ****P < 0.0001; NS (not significant), P > 0.05. (Scale bars: 100 μm.) angiogenesis in vivo (26) . As a control, CPS49, a well-characterized antiangiogenic analog of Thalidomide (26), also was used in these experiments. Drugs were added to 24 hpf embryos and the effect on intersomite blood vessel development analyzed 24 h later. In agreement with our previous results (26), we found that CPS49 (10 μg/mL; n = 10) completely blocked blood-vessel development, resulting in a significant decrease in both stalk number and length compared with vehicle alone (0.1% DMSO) controls (Fig. 3 B- B′, E, and F; n = 10). Lenalidomide (200 μg/ mL) had a similar, but less severe, impact on blood-vessel formation, decreasing stalk length, but not stalk number (Fig. 3 C-C′ , E, and F; n = 10). In contrast, in embryos treated with Pomalidomide at its maximally anti-inflammatory concentration (60 μg/ mL), blood-vessel formation was indistinguishable from controls ( Fig. 3 D- D′, E, F; n = 10).
Because Lenalidomide, but not Pomalidomide, inhibits blood vessel formation, next we asked if endothelial cells are differentially sensitive to these compounds. To address this question, we used the human umbilical vein endothelial cell (HUVEC) tube assembly assay (26) . HUVECs were plated on an ECMatrix gel, incubated for 18 h in the presence of compounds, then imaged and analyzed. We found that CPS49 (10 μg/mL; n = 13) and Lenalidomide (200 μg/mL; n = 15) inhibited completely vascular lattice formation (Fig. 3 H-I and K) . In contrast, angiogenic growth occurred normally in the presence of Pomalidomide (60 μg/mL; n = 14; Fig. 3 J and K) . Previously we have shown that the antiangiogenic activity of CPS49 correlates with organizational changes of endothelial cytoskeletal elements important for cell migration and proliferation (26) . Thus, CPS49 inhibits α-tubulin and increases F-actin assembly (Fig. 3 M-M′ and P-Q). We found Lenalidomide induced similar changes in HUVEC cytoskeletal organization (Fig. 3 N-N′ and P-Q), whereas Pomalidomide had no detectable effect on either α-Tubulin or F-actin assembly (Fig. 3 O-O′ and P-Q).
Because COX2 is important for both inflammation and angiogenesis (16), next we tested the effect of each compound on the up-regulation of COX2 in HUVEC in response to stimulation with VEGF-A (10 ng/mL; Fig. 3R ). We found that, compared with the DMSO control (n = 6), Lenalidomide (n = 8) abrogated the VEGF-A-induced stimulation of COX2 (Fig. 3R) . However, in marked contrast to macrophage cells in which Pomalidomide inhibited COX2 expression (Fig. 1J) , Pomalidomide (n = 8) had no effect on COX2 expression in HUVEC (Fig.  3R) . We conclude that endothelial cells are selectively sensitive to Lenalidomide but not Pomalidomide at the concentrations tested. 5, 10, 11 ). However, whether Thalidomide, or any of its analogs, has direct effects on neurons has not been established in previous studies. To test this idea, we used an established mouse retinal explant outgrowth assay (30) . Explants were prepared from embryonic (E) 14.5 mouse retina and explanted in collagen gels in presence of compounds diluted in serum-free medium. After 18 h, the cultures were fixed, stained with a neuron-specific anti-β-tubulin antibody, and the area covered by the retinal axons, a measure of both axon length and number, quantified (30) . We found that both Thalidomide (250 μg/mL; n = 42) and Lenalidomide (200 μg/mL; n = 42), decreased significantly the extent of neural outgrowth compared with vehicle alone (0.1% DMSO) controls (n = 62), with only a few short axons extending from each explant (Fig. 4 A-C and E) . In contrast, profuse outgrowth occurred in the presence of Pomalidomide (60 μg/mL; n = 25; Fig. 4D) , with no significant difference in the extent of outgrowth relative to controls (Fig. 4E) . We conclude that at potent anti-inflammatory concentrations Thalidomide and Lenalidomide, but not Pomalidomide, have direct inhibitory effects on neurite outgrowth.
Discussion
Pomalidomide has been shown to be effective at reducing TNF-α in vitro (18, 19) . However, the in vivo actions of Pomalidomide upon the embryo, blood vessels, and nerves-all of which are targets of Thalidomide-remain unclear. Using in vivo embryonic assays and in vitro cell cultures we have compared and contrasted the functions and activities of Thalidomide, Lenalidomide, and Pomalidomide. We have demonstrated that Pomalidomide has no detectable effects upon blood-vessel formation, neurite growth, or embryonic development at maximally anti-inflammatory concentrations, unlike Thalidomide and Lenalidomide. Our in vivo and in vitro assays also demonstrate that Pomalidomide is highly Graphs represent mean ± SEM *P < 0.05; **P < 0.005; ***P < 0.0005, ****P < 0.0001; NS, P > 0.05. Scale bars: A-D′ and F-H′, 1,000 μm; J-L′, 200 μm.
anti-inflammatory at substantially lower concentrations than Thalidomide or Lenalidomide, the drugs licensed currently for clinical use. Moreover, in marked contrast to Thalidomide and Lenalidomide, at its maximally effective anti-inflammatory concentration, Pomalidomide was selective for macrophage cells. Thus, Pomalidomide does not inhibit COX2 production in vascular cells following angiogenic stimulation, but is a potent COX2 inhibitor in inflammatory response cells at the same concentration. A similar effect has been demonstrated in monocyte cell lines (16) suggesting Pomalidomide targets inflammatory cells specifically. Together these in vivo and in vitro findings demonstrate that Pomalidomide represents a potent, cell-selective immunomodulatory drug, with a potential for fewer adverse side effects.
The concentrations of each compound tested and identified as the most potent in reducing TNF-α production has also been demonstrated in other in vitro studies monitoring TNF-α inhibition in LPS-stimulated RAW 264.7 cells or peripheral blood mononuclear cells (17, 18, 21, 31) . In fact a broad range of concentrations have been tested in vitro to study actions of Pomalidomide (18, 19, 32) . In chicken and zebrafish embryos, Pomalidomide activity has not previously been tested, but concentrations used are similar to the concentrations of Thalidomide used in other teratogenic studies (23, 24, 26, 28, 33) .
Pomalidomide has been shown to exert its pharmacological properties through the parent molecule, with breakdown products showing little activity (34) . In contrast, Thalidomide is known to require breakdown into active byproducts (3), and previous studies have shown that it is the antiangiogenic breakdown products of Thalidomide that cause teratogenic defects (26) . Pomalidomide has been shown to be weakly antiangiogenic in a VEGF-stimulated HUVEC assay (35) . However, the effect was subtle and observations upon the endothelial cell and its cytoskeleton were not demonstrated. In contrast we demonstrate To confirm angiogenic sensitivity, HUVEC were plated on ECMatrix and incubated for 18 h. (G-J) Angiogenic growth following compound or DMSO incubation indicates Pomalidomide has no effect as quantified by measuring area of filopodia outgrowth (K). (L-O′) HUVEC were treated with drug or DMSO, then analyzed for α-tubulin (green) and F-actin (red). DNA was visualized with Hoechst dye (blue). HUVEC were treated with 0.1% DMSO, CPS49 10 μg/mL, Lenalidomide 200 μg/mL, or Pomalidomide 60 μg/mL for 4 h, then fixed and stained. (P and Q) Fluorescence intensity (FI) for F-actin and α-tubulin was measured. F-actin was up-regulated following CPS49 treatment and α-tubulin was down-regulated with antiangiogenic drugs. (R) Here, qRT-PCR showed a significant decrease in COX2 expression following Lenalidomide, but not Pomalidomide treatment. (E and F) Statistical significance was analyzed using two-way ANOVA with Bonferroni posttest or (K, P-R) one-way ANOVA with Tukey's post hoc test; *P < 0.05; **P < 0.005, ***P < 0.0005; ****P < 0.0001; NS, P > 0.05, FI represent fluorescent intensity. (Scale bars: 100 μm.)
at highly anti-inflammatory concentrations, determined from in vivo embryonic assays, Pomalidomide has no effect on angiogenesis in vivo zebrafish embryos nor in vitro HUVEC cultures, unlike Lenalidomide. Moreover we observed no changes in the actin cytoskeleton of endothelial cells following Pomalidomide exposure, unlike Lenalidomide, which suggests that Pomalidomide does not target endothelial cells at the anti-inflammatory concentrations tested in this study. The cell-selective properties of this drug corroborate studies demonstrating Pomalidomide inhibits immune-system cells and not endothelial cells (16) . The selective activity of Pomalidomide in this study could be due to an absence of antiangiogenic breakdown products. Conversely structural changes in Pomalidomide relative to Thalidomide may prevent the drug from interacting with noninflammatory cells. Determining the molecular targets and signaling pathways facilitating the cell-specific action will shed light on the mechanisms of action of each of these compounds. Many molecular targets have been suggested but the precise molecular pathways involved in anti-inflammation as well as teratogenesis remain to be elucidated (2, 22, 23, 27, 36, 37) . Irrespective of the underlying mechanisms, our findings demonstrate that Pomalidomide, but not Thalidomide and Lenalidomide, is specific for inflammatory response cells.
Lenalidomide has been reported previously to be nonteratogenic based on studies in rabbits (12) . Our studies show a clear teratogenic effect of Lenalidomide on both chicken and zebrafish embryos at the concentration required to induce an antiinflammatory response. Our studies further demonstrate that Lenalidomide, in contrast to Pomalidomide, is not selective for inflammatory cells and also affects blood vessels and nerves. Although the limb defects induced by Lenalidomide were less severe than those resulting from exposure to Thalidomide or its antiantiangiogenic analog CPS49 (26) , comparable eye defects were observed as well as facial defects not seen with the other compounds. In vitro approaches and in vivo observation in adult rats have demonstrated that Lenalidomide can be antiangiogenic (35, 38) , and we have further confirmed that this is also true in vivo in the embryo. The teratogenic effects of Thalidomide are mediated, at least in part, through inhibition of blood-vessel formation (26) . Thus, the antiangiogenic activity of Lenalidomide may also explain the detrimental effects of this drug on embryonic development.
Both Lenalidomide and Pomalidomide are used to treat multiple myeloma (8) (9) (10) . Pomalidomide is particularly effective in patients experiencing relapsed multiple myeloma (13) (14) (15) . The precise mechanisms underlying the causes of multiple myeloma remain unclear, although an involvement of angiogenesis and inflammation are widely supported (39, 40) . Our data suggests, in some patients, that the potent anti-inflammatory action of Pomalidomide could be critical in the treatment/management of this condition.
A major side effect of Thalidomide and Lenalidomide longterm clinical use in adults is peripheral neuropathy. However, it is unclear whether the compounds have direct effects on neurons, or if the neuronal damage occurs secondary to, for example, vascular damage (5, 41) . In contrast to Pomalidomide, our findings demonstrate a direct, detrimental effect of both Thalidomide and Lenalidomide on neurons. Neuronal growth was potently inhibited, with explant death occurring in some cases. This strongly suggests that direct neurotoxic effects underlie the peripheral neuropathy suffered by patients taking Thalidomide or Lenalidomide for long-term therapies, although further studies will be required to confirm this.
Nerves and blood vessels display remarkable similarities in the cellular mechanisms controlling their development. In particular, endothelial tip cells and neuronal growth cones, the structures essential for driving vascular and neuronal growth, respectively, both contain a highly dynamic cytoskeleton essential for locomotion and directionality (42) . Our findings demonstrate a direct effect of Lenalidomide, but not Pomalidomide, on organization of the cell cytoskeleton, including a loss of tubulin. Loss of tubulin likely underlies the effect of Lenalidomide on vascular and neuronal development. Previous work has demonstrated Thalidomide and CPS49 also reduce tubulin in endothelial cell cytoskeleton (26, 33) . These findings suggest that effects on the cell cytoskeleton represent a final common path of action of Lenalidomide and Thalidomide on susceptible cells.
Our findings in zebrafish and chicken embryos indicate that at highly anti-inflammatory concentrations, Pomalidomide is not teratogenic. A recent study discussed regulatory guidelines issued by the US Food and Drug Administration, which has indicated that Pomalidomide (and Lenalidomide) may be teratogenic in some mammalian species (32) . It is well known that Thalidomide exhibits species-specific differences in teratogenesis (1, 2) . The basis of these species-specific differences remains unclear, and requires further detailed analysis, but could shed light on molecular targets and perhaps to safer and more targeted forms of these compounds. In summary, our studies, in chicken and zebrafish embryos, indicate Pomalidomide is more potently antiinflammatory in vivo at lower doses than Lenalidomide and Thalidomide with no adverse side effect. Our findings, and assays, also validate the approach of making structural analogs of Thalidomide to identify more potent and tissue-specific forms of the drug with minimal or reduced side effects.
Materials and Methods
Compounds. Thalidomide and Pomalidomide were purchased from Sigma. Lenalidomide was obtained from Sequoia Research Products, United Kingdom Compounds were dissolved in DMSO-final working DMSO concentration was 0.1% and applied as described previously (26) .
Zebrafish Embryology. Tg(MPO::EGFP) 114 (72 hpf; obtained from the University of Sheffield) zebrafish were sedated, tail fin wounded, then incubated with compound or DMSO (dissolved in aquarium water) for 24 h as established (20) . Fish were imaged and the number of fluorescent cells (neutrophils) was counted. Effects of compounds on vessels were carried out on Fli1:EGFP embryos (obtained from the Zebrafish International Resource Center) as previously described (26, 29) .
Chicken Embryology. Fertilized white leghorn chicken embryos (Henry Stewart Ltd., Herefordshire, United Kingdom) were staged as described previously (26) . (E) Quantification of neurite outgrowth, indicating Pomalidomide has no effect on neurite outgrowth. Statistical significance was analyzed one-way ANOVA with Tukey's post hoc test. Graphs represent mean ± SEM *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001; NS, P > 0.05. (Scale bar: 300 μm.)
